However, RAS blockade can promote the development of hyperkalemia, especially when combined with mineralocorticoid receptor antagonists (MRAs), potentially limiting their use or the achievable target doses in patients with glomerular diseases. Here, NR3C2 is linked to Hyperkalemia.